Group 1 - The core issue of the article revolves around the impact of Trump's administration on the global economic order, particularly in the realm of international tax rules and trade [1] - The G7 countries have been forced to accept exemptions for U.S. companies from certain tax rules, indicating a shift in international tax dynamics [2] - The compromise reached may lead to future conflicts, particularly regarding digital taxes, as countries like the UK, France, Spain, and Italy have already implemented similar taxes [3] Group 2 - The U.S. tax supremacy ideology has emerged, with bipartisan support in Washington against foreign extraterritorial taxation [2] - The agreement to exempt U.S. companies from specific rules may set a precedent for future negotiations, raising concerns about the credibility of U.S. commitments [3] - The complexity of the dual taxation system is increasing for multinational companies, leading to greater policy uncertainty and higher cross-border operational costs [3]

证券研究报告 | 金融工程 gszqdatemark 2025 07 01 年 月 日 量化分析报告 "薪火"量化分析系列研究（五） 如何利用 DeepSeek 辅助降低跟踪误差 研究背景：证监会于近期发布了《推动公募基金高质量发展行动方案》，基 金管理者未来或将更加重视基准，锚定基准创造超额收益。本篇报告结合 上述热点话题，探索 DeepSeek 能否辅助基金管理者降低产品相对于基准 的跟踪误差。具体地，本报告首先利用 DeepSeek 的联网搜索、深度思考 功能给出降低跟踪误差的方案，接着按照其给出的方案，要求 DeepSeek 设计策略落地方法及组合构建代码，展示对应方案下组合的改进效果。 方案①：核心卫星化，增加基准成份股权重 DeepSeek 给出的最容易实现降低跟踪误差的方法为核心卫星化：拿出部 分仓位直接配置基准指数，剩余仓位进行主动管理。针对核心卫星化方案， DeepSeek 给出了通过网格搜索法获得最优参数、构建组合的代码。此外， 针对基准指数成份股太多、较难完全复制的问题，DeepSeek 进一步给出 了基准指数替代组合的构建方法。 方案②：行业中性化，专注于选股打败行业指数 作者 分析师 ...

Core Insights - AIM ImmunoTech Inc. presented its drug Ampligen at the U.S.-Poland Science and Technology Symposium 2025, highlighting its potential in immunotherapy [1][2] - Dr. Pawel Kalinski emphasized the importance of public-private partnerships in advancing cancer research and treatment development [2][4] - The conference focused on "Opportunities in Singularity," showcasing collaboration between various institutions and organizations [3] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [5] - Ampligen, the company's lead product, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist with broad-spectrum activity in clinical trials [5] Future Initiatives - The CEO of AIM stated the goal of establishing clinical partnerships and licensing agreements in Europe, particularly in Poland, to enhance cancer research [4]

Core Insights - PharmaTher Holdings Ltd. aims to become a global leader in ketamine-based pharmaceuticals, with a clear strategy for regulatory approval and international expansion [1][3] Regulatory Milestones - The FDA has set an approval goal date of August 9, 2025, which is a significant milestone for the company, potentially unlocking a multi-billion-dollar market opportunity [3][7] - The current global market for ketamine is valued at $750 million and is projected to grow at a CAGR of 16.4%, reaching approximately $3.42 billion by 2034 [3] Financial Position - The company is fully funded for all planned operations leading up to the FDA approval goal date and the initial U.S. commercial launch of its ketamine product [5][7] - PharmaTher has no plans for new equity or debt financing before the FDA approval date, indicating confidence in its current financial position [6][7] Commercial Strategy - The manufacturing of the ketamine product is based in the U.S., ensuring supply chain security and quality control [7][8] - PharmaTher is preparing for international regulatory submissions in Europe, the UK, Canada, Japan, and the APAC regions, expected to begin in the second half of 2025 [7][8] Expansion and Innovation - The company is exploring new therapeutic applications for ketamine, inspired by bipartisan support for psychedelic-assisted therapies [9] - PharmaTher aims to broaden its clinical pipeline, focusing on indications such as Parkinson's disease, ALS, and CRPS, as well as novel delivery systems [7][9] Leadership Vision - The CEO emphasizes the upcoming FDA approval goal date as a critical starting point for global expansion and new therapeutic indications [10]

Psychedelic Medicine - Psychedelic medicine 行业关注 psilocybin（一种迷幻蘑菇中的活性成分）的潜力，这得益于最近的一项研究 [1] - Ibogaine（一种从非洲灌木 Iboga 中提取的物质）也被 Psychedelic medicine 行业关注，因为各州正在努力批准相关药物 [1]

So much less pleasurable this way, sold last week for $0.02 USD ama https://t.co/ucgvSYgd5vwale.moca 🐳 (@waleswoosh):My guilty pleasure is checking the charts of airdrops I sold months ago and seeing how much money I saved by selling them ...

Velodrome enables native cross-chain swaps for its DEX ecosystem on Optimism Superchain https://t.co/e9d0KFm4jD ...

经济学家预测，6月非农就业报告将显示就业增长放缓，失业率小幅上升，因为关税和移民政策的不确定性正在影响美国经济。 （月度非农变化 来源：美国劳工部） 6月就业报告预测重点： 发布时间：美东时间7月3日周四上午8:30 根据FactSet的共识预期，6月非农就业人数预计新增11.5万人，低于5月的13.9万人；失业率预计从5月的4.2%升至4.3%。 贝莱德全球固定收益董事总经理、总回报基金（MAHQX）管理人David Rogal表示："我们看到劳动力市场正在放缓，但尚无恐慌迹象。我们预期的就业 增长处于10万出头的温和水平。" 每周公布的持续申请失业救济人数是显示6月就业市场走弱的早期信号。瑞银经济学家指出，"高频指标显示过去6至8周劳动力市场有所减弱"，他们预计6 月新增就业为10万人。 瑞银表示："我们预计由于TPS相关的裁员将影响就业数据，但具体影响程度和是否会在调查中反映出来仍不确定。" 他们估计这部分可能导致6月就业减 少约5,000人。 高盛则预计，6月新增就业将仅为8.5万人，低于市场预期，并指出TPS政策可能导致非农就业减少2.5万人。 另一个不确定因素是7月9日特朗普设定的关税暂停期到期。 ...

今日（7.2）港股多数飘红，恒科逆市回调。恒生科技ETF基金（513260）盘中跌超1%，溢价频现。值得关注的是，恒生科 技ETF基金（513260）是同类唯一费率最低档的产品，管理费率仅0.15%。 | 5分 15分 30分 60分 = 综合屏 F9 前复权 超级叠加 画线 工具 ♡ ② > | | 恒生科技ETF基金 ① | | 513260 | | --- | --- | --- | --- | --- | | 夜ETF基金] 2025/06/27 枚1.375 幅0.36%(0.005) 开1.379 高1.387 低 1.371 均1.37@ | | 1.356 | | -0.014 -1.02% | | 1.3531 MA20 1.3591 MA60 1.3451 MA120 1.3561 MA250 1.1881 (90日) 7 = | | | | | | | | | SSE CNY 13:37:10 交易中 T+0 船 / Q + | | | 1.60 | | 净值走势 | | 汇添富恒生科技ETF | | | | | 12.00% 委差 | 39398 | | | 委比 | | | | | ...

July 1, 2025 03:00 PM GMT Internet names rose +7% last week (SPX/NDX +3%/+4%) led by META/GOOGL/AMZN +8%/+7%/+6%. Markets reached all-time highs amid trade negotiation progress as we enter 2Q preview season. Fundamental focus ahead. AMZN/GOOGL/META 31X/18X/27X '26 EPS (+1%/-4%/+20% vs TTM avg). | M | | | | --- | --- | --- | | | | Update | | July 1, 2025 03:00 PM GMT Internet North America | Morgan Stanley & Co. LLC | | | | Brian Nowak, CFA | | | | Equity Analyst | | | Where Are We Trading Now: | Brian.Nowak ...